For those with a high amount of the protein, AZD5335 will be compared to mirvetuximab soravtansine. For those with a low amount of the protein, AZD5335 will be compared to a treatment chosen by the doctor, which may include doxorubicin hydrochloride, liposomal, topotecan, or paclitaxel. These treatments are delivered through an intravenous infusion, which means the medicine is passed directly into a vein.

During the study, participants will receive their assigned treatment and will be monitored to see how long the cancer remains stable without growing. This period is referred to as progression-free survival. The study also looks at overall survival, which is the total length of time from the start of the study until death from any cause.

The study is divided into different parts. In the first parts, called Part A, Part B, and Part C, researchers will test different doses of the drug to find out which dose is safe and works best. They will carefully watch for any side effects and see how the body processes the drug. In Part D, the study will focus specifically on people with pancreatic adenocarcinoma and will look more closely at whether the drug helps shrink tumors or stop them from growing. During the study, participants will receive the study drug and will have regular check-ups to monitor their health and see how the cancer is responding to treatment.

Throughout all parts of the study, doctors will measure how much of the drug is in the blood, watch for any unwanted effects, and check if the cancer gets better, stays the same, or gets worse. They will also test whether the body develops an immune response to the drug over time. The study will track how long any positive effects last and whether people need to stop treatment or change their dose because of side effects. All participants must have already tried standard treatments that are normally used for their type of cancer, and those treatments must not have worked well enough or must no longer be available as an option.

The study involves two main groups of patients. The first group will receive the medication according to different dosing schedules, while patients with moderate liver problems will be studied separately to find the right starting dose for them. During treatment, patients will receive the medication every three weeks as part of a 21-day cycle. The study will also use prednisolone acetate eye drops and lubricating eye drops as supportive care.

The research team will monitor patients for treatment effectiveness and any side effects, particularly paying attention to eye-related effects. They will track how the cancer responds to treatment through regular medical examinations and imaging tests. The study will also measure how long the treatment keeps working and how long patients survive after starting the treatment.

The purpose of the study is to find the best dose of ETX-19477 that patients can tolerate and to understand how safe it is. The study will also look at how well the drug works against the cancer. The study is divided into two phases. In the first phase, researchers will determine the safest dose and observe any side effects. In the second phase, they will assess how effective the drug is in treating the cancer. Participants will take the medication by mouth and will be monitored regularly to check their health and the cancer’s response to the treatment.

Throughout the study, participants will have regular check-ups to monitor their health and any changes in their cancer. The study aims to provide valuable information about the potential benefits and risks of using ETX-19477 for treating advanced solid cancers. This research could lead to new treatment options for patients with these types of cancers in the future.

The trial will include patients with various types of advanced cancers, such as non-small cell lung cancer, renal cell carcinoma, urothelial bladder cancer, head and neck squamous cell cancer, breast cancer, gastric or gastroesophageal adenocarcinoma, epithelial ovarian cancer, cervical cancer, endometrial adenocarcinoma, prostate cancer, and soft tissue sarcoma. The study will be conducted in two phases. The first phase will focus on finding the right dose of JK06 by gradually increasing the amount given to patients. The second phase will involve giving the selected dose to more patients to further evaluate its effects.

Throughout the study, patients will receive the treatment every three weeks and will be monitored closely for any side effects or changes in their condition. The goal is to gather information that will help in developing JK06 as a potential treatment option for people with these types of advanced cancers. The study is expected to continue until 2028, with recruitment starting in 2024.

The purpose of the study is to determine the best dose of IMGN151 that can be safely given to patients and to see how well it works in treating these cancers. The study will be conducted in two main phases. In the first phase, different doses of IMGN151 will be tested to find the safest and most effective dose. In the second phase, the chosen dose will be given to more patients to further assess its effectiveness. Throughout the study, participants will receive IMGN151 through an intravenous infusion, which means the medication will be delivered directly into the bloodstream through a vein.

Participants in the study will be closely monitored for any side effects and to see how their cancer responds to the treatment. The study aims to provide valuable information about the potential benefits and risks of IMGN151 for women with these specific types of recurrent cancers. This research is important for developing new treatment options that could improve outcomes for patients facing these challenging conditions.

Participants in the study will be randomly assigned to receive either letrozole or a placebo, which is a tablet that looks like the medication but does not contain any active ingredients. The study is designed to be double-blinded, meaning neither the participants nor the researchers will know who is receiving letrozole and who is receiving the placebo. This helps ensure that the results are not influenced by expectations about the treatment. The main goal is to see if letrozole can help extend the time patients live without their cancer getting worse, known as progression-free survival.

The study will take place over a period of time, with participants taking the medication or placebo orally for up to 60 months. Throughout the study, participants will have regular check-ups to monitor their health and the status of their cancer. The researchers will also look at other outcomes, such as overall survival and quality of life, to understand the full impact of letrozole as a maintenance therapy for epithelial ovarian cancer.

Participants in the study will be randomly assigned to one of two groups. One group will receive the HIPEC treatment with cisplatin, while the other group will not receive HIPEC. The study will monitor the participants over a period to assess their overall survival and any side effects they may experience. The study will also look at other factors such as the time until the cancer returns, the quality of life of the participants, and any pain they may experience.

Throughout the study, various assessments will be conducted to gather information on the effectiveness and safety of the treatment. This includes monitoring for any complications or side effects, particularly focusing on kidney health, as well as evaluating the participants’ quality of life and pain levels. The study aims to provide valuable insights into whether HIPEC with cisplatin can be a beneficial treatment option for patients with recurrent ovarian cancer.

Participants in the study will be divided into different groups to receive either the medications or a placebo. The study will compare the effects of taking Rucaparib alone, Rucaparib combined with Nivolumab, or a placebo. The trial will monitor the progression of the disease and overall survival rates among participants. The study aims to determine if these treatments can help maintain the positive effects of the initial chemotherapy and delay the progression of the cancer.

The trial will be conducted over several years, with participants receiving treatment and being monitored for any changes in their condition. The study will use specific criteria to evaluate the effectiveness of the treatments, such as the time it takes for the disease to progress or for any adverse effects to occur. The results will help determine the potential benefits of using Rucaparib and Nivolumab as part of a long-term treatment plan for patients with advanced ovarian cancer.

The purpose of the study is to determine how well these treatments work in shrinking or controlling the tumors, as well as to assess their safety. Participants will receive one of the treatments based on the specific characteristics of their cancer. The study will monitor the response of the tumors to the treatment and any side effects experienced by the participants. The study is designed to last for a certain period, during which participants will have regular check-ups and tests to track their progress.

Throughout the study, participants will be closely monitored by healthcare professionals to ensure their safety and to gather information on how the treatments affect their cancer. The results of this study will help in understanding which treatments are most effective for these rare types of ovarian cancer and could lead to better treatment options in the future.

In addition to carboplatin and paclitaxel, the study will also involve the use of bevacizumab, a medication that helps prevent the growth of blood vessels that supply the tumor, and filgrastim, which is used to boost white blood cell counts and help the body fight infections during chemotherapy. Some patients in the study will receive a placebo instead of bevacizumab to compare the effects. The trial aims to determine if the new treatment plan can improve outcomes for patients, such as increasing the chances of successful surgery and extending survival times.

Participants in the study will receive treatment over a period of up to 64 weeks. The study will monitor various outcomes, including the overall response to treatment, progression-free survival (the time during which the cancer does not get worse), and overall survival. The trial will also assess the quality of life of participants and gather information on any side effects experienced. The findings from this study could help improve treatment strategies for patients with ovarian cancer who have a poor prognosis.

The purpose of the study is to explore how the body processes niraparib and how this might relate to side effects, particularly those affecting the blood and kidneys. The study will look at different factors that might influence these side effects, such as individual patient characteristics and how the drug is absorbed and used by the body. Participants will receive either a standard dose of 300 mg per day or a reduced dose of 200 mg per day, depending on the doctor’s decision.

Throughout the study, researchers will monitor the participants’ health and any side effects they experience. They will also assess the quality of life of the participants and how it relates to any side effects observed. The study aims to identify factors that could predict side effects and to develop models that could help in understanding these effects better. The study is expected to continue until 2029, with recruitment starting in 2024.

Participants in the study will receive an injection of these substances, which will help in identifying the sentinel lymph nodes. The study will assess how well these substances work in detecting the lymph nodes and whether they provide accurate results. The trial will also look at the location of the sentinel lymph nodes and any potential complications that might arise from using these substances.

The purpose of this study is to improve the diagnostic process for patients with early-stage epithelial ovarian cancer by using these substances to better identify sentinel lymph nodes. This could potentially lead to more accurate staging of the cancer and help in planning the most effective treatment. The study is expected to continue until 2026, with the aim of gathering comprehensive data on the effectiveness and safety of these diagnostic agents.

The purpose of this study is to compare the effectiveness of the combination of mirvetuximab soravtansine and bevacizumab with bevacizumab alone in maintaining the health of patients who have not shown disease progression after receiving platinum-based chemotherapy. Patients will be randomly assigned to receive either the combination treatment or bevacizumab alone. The study will monitor the patients over a period to assess how long they remain free from cancer progression. This is known as progression-free survival, which is a measure of how long patients live without the cancer getting worse.

Participants in the study will receive the treatments as an infusion, which means the medication is delivered directly into the bloodstream through a vein. The study will also involve regular check-ups and assessments to monitor the patients’ health and any side effects they may experience. The trial aims to provide valuable information on whether the combination of mirvetuximab soravtansine and bevacizumab offers better outcomes for patients compared to bevacizumab alone. This research could potentially lead to improved treatment options for individuals with these types of cancers.

The study will be conducted in two main parts. In the first part, the treatment will be given alone to see how patients tolerate it and to determine the best dose. In the second part, the treatment will be combined with standard cancer treatments to see if it works better together. Throughout the study, researchers will monitor patients closely to ensure their safety and to gather information on how the treatment affects their cancer.

Participants in the study will take the treatment in the form of a tablet by mouth. The study will involve regular check-ups and tests to track the treatment’s effects and any side effects. The goal is to find out if GTAEXS617 can be a safe and effective option for treating advanced solid tumors.

The purpose of the study is to evaluate how well the combination of Carboplatin and Mirvetuximab Soravtansine works in treating these cancers. Initially, patients will receive both Carboplatin and Mirvetuximab Soravtansine together. After this phase, patients will continue treatment with Mirvetuximab Soravtansine alone. The study aims to see if this treatment approach can help control the cancer in patients who have shown sensitivity to platinum-based chemotherapy in the past.

Participants in the study will receive the treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will monitor the response of the cancer to the treatment over time. This trial is open-label, meaning both the researchers and participants know which treatments are being administered. The study will help determine the effectiveness of this treatment combination in managing these specific types of cancer.

Participants in the study will receive chemotherapy with or without pembrolizumab, followed by maintenance treatment with olaparib or a placebo. The study will be conducted over a period of time, with regular monitoring to assess the progression of the disease. The treatments will be administered through intravenous infusions or oral tablets, depending on the specific medication.

The study aims to provide valuable information on how these treatments can help manage advanced epithelial ovarian cancer, particularly in patients without BRCA mutations. The results will help determine the best treatment options for improving the quality of life and survival rates for individuals with this type of cancer.

The study is designed to determine if mirvetuximab soravtansine works better than standard chemotherapy treatments. The main goal is to measure how long patients live without their cancer getting worse. The study will also look at how well patients respond to treatment, overall survival time, quality of life, and any side effects that may occur.

Participants will be randomly assigned to receive either mirvetuximab soravtansine or one of the standard chemotherapy medications through intravenous infusion. The treatment will continue for several months, with regular check-ups to monitor the cancer’s response to treatment and any side effects. The study is expected to run until mid-2025.